Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer

Kimura Michio; Usami Eiseki; Teramachi Hitomi; Yoshimura Tomoaki

首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer

【24h】

Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer

机译：Ramucirumab加上紫杉醇化疗治疗先进和复发性胃癌的成本效益和安全性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction Weekly paclitaxel (PTX), irinotecan (CPT-11) and ramucirumab plus paclitaxel (Ram+PTX) are currently recommended as the standard second-line or later chemotherapies for advanced and recurrent gastric cancer. This study aims to compare the cost-effectiveness of using Ram+PTX vs. PTX or CPT-11. Furthermore, we investigated the safety and treatment continuity of Ram+PTX in Japan.

机译：引言每周紫杉醇（PTX），Irinotecan（CPT-11）和Ramucirumab Plus Paclitaxel（RAM + PTX）目前建议作为先进和复发性胃癌的标准第二线或后期化学疗法。本研究旨在比较使用RAM + PTX与PTX或CPT-11的成本效益。此外，我们调查了日本Ram + PTX的安全性和治疗连续性。

著录项

来源
《Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners》 |2018年第6期|共9页
作者
Kimura Michio; Usami Eiseki; Teramachi Hitomi; Yoshimura Tomoaki;
展开▼
作者单位

Ogaki Municipal Hosp Dept Pharm 4-86 Minaminokawa Cho Ogaki Gifu 5038502 Japan;

Ogaki Municipal Hosp Dept Pharm 4-86 Minaminokawa Cho Ogaki Gifu 5038502 Japan;

Gifu Pharmaceut Univ Lab Clin Pharm Gifu Japan;

Ogaki Municipal Hosp Dept Pharm 4-86 Minaminokawa Cho Ogaki Gifu 5038502 Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
Ramucirumab; paclitaxel; cost-effectiveness; adverse event; advanced and recurrent gastric cancer;

机译：Ramucirumab;Paclitaxel;成本效益;不良事件;先进和经常性胃癌;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer [J] . Kimura Michio, Usami Eiseki, Teramachi Hitomi, Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2018,第6期

机译：Ramucirumab加上紫杉醇化疗治疗先进和复发性胃癌的成本效益和安全性
2. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites [J] . Hiroshi Matsumoto, Akihito Kawazoe, Kaoru Shimada, BMC Cancer . 2018,第1期

机译：回顾性研究紫杉醇加紫苏尿液与腹水先进或复发胃癌患者的安全性和疗效研究
3. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis [J] . Ecological restoration . 2020,第2期

机译：Nab-Paclitaxel Plus Ramucirumab和Paclitaxel Plus Ramucirumab作为腹膜癌症治疗腹膜转移的晚期治疗的回顾性比较
4. Effects of Weekly Paclitaxel as a Second-Iine Anticancer Chemotherapy for Patients with Advanced and Recurrent Gastric Carcinoma [C] . Y. Sakurai, I. Yoshida, T. Masui, International Gastric Cancer Congress . 2005

机译：每周紫杉醇作为先进和复发性胃癌患者的二缘抗癌化疗的影响
5. Treatment Patterns and Cost-Effectiveness of Chemotherapy Treatments among Advanced Gastric Cancer Patients [D] . Haag, Austin Jade. 2017

机译：晚期胃癌患者化学疗法的治疗模式和成本效益
6. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group [O] . Kenro Hirata, Yasuo Hamamoto, Masahiko Ando, 2020

机译：每周紫杉醇联合雷莫昔单抗与每周纳布紫杉醇联合雷莫西单抗治疗无法切除的晚期或复发性胃癌但一线治疗难治性腹膜扩散-P-SELECT试验（WJOG10617G）-西日本肿瘤学小组的一项随机II期试验
7. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group [O] . Kenro Hirata, Yasuo Hamamoto, Masahiko Ando, 2020

机译：每周Paclitaxel Plus Ramucirumab与每周Nab-Paclitaxel加上Ramucirumab与腹膜传播难以进行一线治疗 - P-SELECT试验（WJOG10617G）-A由西日本肿瘤学组进行随机化第二次审判

Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer

摘要

著录项

相似文献

相关主题

期刊订阅